Formulation and Characterization of Transethosomes for Enhanced Transdermal Delivery of Propranolol Hydrochloride

Kumar, Lalit

doi:10.2174/1876402911666190603093550

Cited by 29 publications

(8 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kumar and Utreja (2020) developed TEs gel using propranolol hydrochloride (PPLH), Lipoid S100 (phospholipid), and permeation enhancer (oleic acid). While using in‐vitro skin permeation study (Confocal Laser Scanning Microscopy—CLSM) and in vivo plasma concentration on Sprague‐Dawley rats, he established whether or not the drug is delivered in a sustained fashion.…”

Section: Research Based Consideration Of Tesmentioning

confidence: 99%

“…The authors reported in in‐vivo method exhibited that TEs successfully released the drug for up to 24 h, with a peak plasma concentration (C max ) of 93.83 ng/mL, which was significantly higher than the commercially available oral tablet of PPLH (45.63 ng/mL). In conclusion, the researcher concluded that the formulated TEs gel of PPLH could be a superior alternative to oral PPLH because it can circumvent the major drawbacks of oral PPLH especially the first‐pass metabolism effect, organ toxicity, and the need for frequent dosage (Kumar & Utreja, 2020). While using full factorial design, Albash et al (2019) formulated Olmesartan medoxomil (OLM) TEs by considering several surfactants (Tween 20 and 80; Span and 60; sodium deoxycholate at 5, 15 and 25 mg each) and in different phospholipid (Phospholipid at 75, 85, and 95 mg each) to surfactant ratios by employing thin‐film hydration method.…”

Section: Research Based Consideration Of Tesmentioning

confidence: 99%

“…Due to advancements in drug delivery, older drugs cannot compete in the expanding pharmaceutical market. Drug delivery technology improves patient adherence, therapeutic index, and bioavailability by modifying the regulated release pattern of drugs (Kumar & Utreja, 2020).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Transethosomes: Cutting edge approach for drug permeation enhancement in transdermal drug delivery system

Nayak¹,

Mohanty²,

Mishra³

et al. 2023

Chem Biol Drug Des

View full text Add to dashboard Cite

The skin is a major route of drug administration. Despite the high surface area of the skin, drug delivery via the skin route is problematic due to its physiological obstacles. The formulation scientist has developed a vesicular system to enhance the skin's absorption of bioactive substances. Among numerous vesicular systems, concept of transethosomes (TEs) introduced in 2012 are being tested for drug delivery to the dermis. When transferosomes and ethosomes interact, TEs are produced. It consists of water, ethanol, phospholipids, and an edge activator. Ethanol and the edge activator increase the absorption of medication through the skin. In the presence of ethanol and an edge activator, skin permeability can increase. The advantages of TEs include increased patient compliance, bypassing first‐pass metabolism, including non‐toxic raw components, being a noninvasive method of drug delivery, being more stable, biocompatible, biodegradable, and administered in semisolid form. TEs can be produced through the use of hot, cold, mechanical dispersion, and conventional techniques. The morphology, shape, size, zeta potential, drug loading efficiency, vesicle yield, biophysical interactions, and stability of TEs define them. Recent studies reported successful transdermal distribution of antifungal, antiviral, anti‐inflammatory, and cardiovascular bioactive while using ethosomes with significant deeper penetration in skin. The review extensively discussed various claims on TEs developed by researchers, patents, and marketed ethosomes. However, till today no patens being granted on TEs. There are still lingering difficulties related to ethanol‐based TEs that require substantial research to fix.

show abstract

Section: Research Based Consideration Of Tesmentioning

confidence: 99%

Section: Research Based Consideration Of Tesmentioning

confidence: 99%

See 1 more Smart Citation

Transethosomes: Cutting edge approach for drug permeation enhancement in transdermal drug delivery system

Nayak¹,

Mohanty²,

Mishra³

et al. 2023

Chem Biol Drug Des

View full text Add to dashboard Cite

show abstract

“…57 Kumar et al found that sustained release of drug can be achieved over 24 h. This can reduce dosing frequency which leads to better patient compliance. 58…”

Section: In Vitro Drug Release Studymentioning

confidence: 99%

Nano-transethosomes: A Novel Tool for Drug Delivery through Skin

Bajaj¹,

Parab²,

Shidhaye³

2021

IJPER

View full text Add to dashboard Cite

Transdermal drug delivery has become a popular tool from last few years. It overcomes drawbacks which are encountered with the oral route. Though very few routes are as attractive as transdermal route, transport of drug through the skin is challenging. In order to overcome the challenges, researchers have found a system in which the drug is encapsulated into the vesicle and these vesicles can penetrate deeper into the skin to hit the target site. Hence, better skin penetration of bioactive agents can be achieved. Vesicular systems like liposomes, niosomes, ethosomes and Transferosomes tend to remain accumulated in the skin layers. Since Transethosomes have small particle size and can easily alter the shape of vesicle as compared with other vesicular systems; it can penetrate through the layers of skin. Hence, the drug encapsulated into Transethosomes can easily reach the target site. Transethosomes consist of ethanol, phospholipids along with an edge activator. Ethanol and edge activator help to enhance skin permeation of Transethosomes. Since it is a non-invasive technique, it improves patient compliance. It also increases drug entrapment efficiency. These vesicles can accommodate different variety of drugs such as anticancer, corticosteroids, proteins and peptides, analgesics.

show abstract

“…Interestingly, various delivery systems were suggested to enhance PRO skin permeation, including polymeric film [ 60 ], iontophoresis [ 61 ], transethosomes [ 62 ], and nanoparticles [ 63 ]. Herein, PRO skin permeability was improved with the development of ufasomes (UFAs), which are non-phospholipid vesicles.…”

Section: Introductionmentioning

confidence: 99%

Sustainable Release of Propranolol Hydrochloride Laden with Biconjugated-Ufasomes Chitosan Hydrogel Attenuates Cisplatin-Induced Sciatic Nerve Damage in In Vitro/In Vivo Evaluation

et al. 2022

View full text Add to dashboard Cite

Peripheral nerve injuries significantly impact patients’ quality of life and poor functional recovery. Chitosan–ufasomes (CTS–UFAs) exhibit biomimetic features, making them a viable choice for developing novel transdermal delivery for neural repair. This study aimed to investigate the role of CTS–UFAs loaded with the propranolol HCl (PRO) as a model drug in enhancing sciatica in cisplatin-induced sciatic nerve damage in rats. Hence, PRO–UFAs were primed, embedding either span 20 or 60 together with oleic acid and cholesterol using a thin-film hydration process based on full factorial design (24). The influence of formulation factors on UFAs’ physicochemical characteristics and the optimum formulation selection were investigated using Design-Expert® software. Based on the optimal UFA formulation, PRO–CTS–UFAs were constructed and characterized using transmission electron microscopy, stability studies, and ex vivo permeation. In vivo trials on rats with a sciatic nerve injury tested the efficacy of PRO–CTS–UFA and PRO–UFA transdermal hydrogels, PRO solution, compared to normal rats. Additionally, oxidative stress and specific apoptotic biomarkers were assessed, supported by a sciatic nerve histopathological study. PRO–UFAs and PRO–CTS–UFAs disclosed entrapment efficiency of 82.72 ± 2.33% and 85.32 ± 2.65%, a particle size of 317.22 ± 6.43 and 336.12 ± 4.9 nm, ζ potential of −62.06 ± 0.07 and 65.24 ± 0.10 mV, and accumulatively released 70.95 ± 8.14% and 64.03 ± 1.9% PRO within 6 h, respectively. Moreover, PRO–CTS–UFAs significantly restored sciatic nerve structure, inhibited the cisplatin-dependent increase in peripheral myelin 22 gene expression and MDA levels, and further re-established sciatic nerve GSH and CAT content. Furthermore, they elicited MBP re-expression, BCL-2 mild expression, and inhibited TNF-α expression. Briefly, our findings proposed that CTS–UFAs are promising to enhance PRO transdermal delivery to manage sciatic nerve damage.

show abstract

Formulation and Characterization of Transethosomes for Enhanced Transdermal Delivery of Propranolol Hydrochloride

Cited by 29 publications

References 23 publications

Transethosomes: Cutting edge approach for drug permeation enhancement in transdermal drug delivery system

Transethosomes: Cutting edge approach for drug permeation enhancement in transdermal drug delivery system

Nano-transethosomes: A Novel Tool for Drug Delivery through Skin

Sustainable Release of Propranolol Hydrochloride Laden with Biconjugated-Ufasomes Chitosan Hydrogel Attenuates Cisplatin-Induced Sciatic Nerve Damage in In Vitro/In Vivo Evaluation

Contact Info

Product

Resources

About